In this episode, ‘IL-17 Inhibition and Long-Term Outcomes in Psoriasis,’ the panelists provide a deeper exploration of IL-17–targeted therapies in psoriasis, focusing on the biological rationale behind different mechanisms of action and how these translate into clinical outcomes. The faculty explored the distinction between selective IL-17A inhibition and dual inhibition of IL-17A and IL-17F, highlighting the evolving understanding of the IL-17 cytokine family and its role in driving inflammation. While IL-17A has historically been considered the primary therapeutic target, emerging insights suggest that IL-17F may also play a significant role due to its higher abundance in psoriatic lesions, raising the possibility that broader pathway inhibition may offer additional clinical benefit.

The faculty examined the complexities of interpreting long-term efficacy data across therapies. While individual clinical trials demonstrate sustained responses over multiple years, they emphasized that differences in study design, patient populations, and statistical methodologies make cross-trial comparisons challenging. Factors such as responder enrichment, rescue criteria, and analytic approaches can significantly influence reported outcomes, underscoring the need for careful interpretation of long-term extension data.

Additionally, the panelists explore the role of real-world evidence as a complementary perspective to clinical trial findings. Although real-world data may introduce variability, it can provide valuable insights into treatment durability and performance in broader patient populations. They also highlight both the benefits and limitations of evaluating therapies aimed at achieving sustained remission in psoriasis.

The next episode in this series, ‘Rapid Response in Psoriasis Treatment,’ the panelists examine the role of rapid treatment response in psoriasis and how speed of efficacy influences treatment decisions and patient satisfaction. It highlights differences within IL-17 inhibitors and the ability to achieve both rapid and sustained disease control without compromising outcomes.